When surgical cartilage repair is no longer the right path

Many patients reach a point in their treatment for hip osteoarthritis where a surgeon has said, plainly, that cartilage repair is no longer appropriate. Understanding why that threshold exists — and what it opens up — is the practical starting point for this article.

Surgical techniques such as microfracture, AMIC, and OATS each depend on the same set of structural conditions: a focal, well-defined cartilage lesion with healthy tissue at its margins; a dry arthroscopic field; and access via a theatre under general or spinal anaesthesia. When those conditions can be met, surgery targets the defect from below — stimulating or transplanting tissue to rebuild the cartilage layer.

Once hip osteoarthritis progresses to Kellgren-Lawrence Grade III or IV, those prerequisites cannot be satisfied. Cartilage loss is no longer isolated to one patch; it is diffuse. There are no healthy margins to anchor a repair. Debridement and bottom-up reconstruction have nowhere to start. The surgical route closes.

At this stage, the clinical question changes: not "how do we rebuild cartilage from below?" but "what can protect and support what remains from above?" ChondroFiller injection is designed precisely for this position — an additive, outpatient treatment that coats worn articular surfaces rather than excising them, and that is relevant specifically because surgery is no longer a realistic option.

What ChondroFiller injection does inside the hip joint

The gel itself is acid-extracted Type I collagen — the same structural protein that gives healthy cartilage its tensile strength — formulated as a high-viscosity liquid and classified as a CE-marked Class III medical device. Delivered under ultrasound or fluoroscopic guidance in a clinic, with no theatre, no general anaesthetic, and no overnight stay, the injection places the collagen directly into the hip joint space.

Once inside the joint, the collagen undergoes rapid in-situ polymerisation on contact with synovial fluid. Rather than remaining as a loose liquid, it sets into a viscoelastic, shock-absorbing barrier that conforms to and coats worn articular surfaces. This is the mechanism sometimes described as an 'extra layer of paint': the material sits over degenerated cartilage, cushioning load and reducing the friction that drives pain, without requiring any debridement of what remains.

Beyond that immediate mechanical effect, the scaffold does something more. Its three-dimensional collagen matrix acts as a chemotactic signal, attracting the patient's own progenitor cells from the surrounding joint environment and supporting a process called matrix-induced chondrogenesis. Over time, those recruited cells can begin producing cartilage-like repair tissue within the scaffold — a regenerative process, not a guaranteed regrowth of cartilage. Published MRI data show progressive structural improvement over twelve months and beyond, though individual outcomes vary and hip-specific long-term data continue to mature.

Because the approach is additive rather than subtractive, it does not compromise the joint structures still present, which matters in a hip where diffuse cartilage loss has already made surgical reconstruction unrealistic.

Where ChondroFiller sits in the hip osteoarthritis treatment hierarchy

Three intra-articular options are currently used at the advanced hip osteoarthritis stage — hyaluronic acid, Arthrosamid, and ChondroFiller injection — and they occupy meaningfully different roles.

Hyaluronic acid (viscosupplementation) restores some of the lubricating properties of synovial fluid that break down in an arthritic hip joint. RCTs including work by Qvistgaard et al. and Clementi et al. confirm that it can reduce pain in symptomatic hip osteoarthritis, and repeated courses have been studied across both high and medium molecular weight formulations. Its purpose is lubrication; it does not provide a structural scaffold, and it does not recruit cells for cartilage repair.

Arthrosamid, a polyacrylamide hydrogel, integrates into the synovial lining and provides a lasting mechanical cushion within the joint space. Like hyaluronic acid, it is not a regenerative scaffold — there is no matrix that supports cell migration or tissue formation.

ChondroFiller injection adds that scaffold dimension. As described in the preceding section, the collagen matrix supports matrix-induced chondrogenesis once in place, in addition to its cushioning role. It is the only outpatient intra-articular option in current use that combines both functions in the hip.

Beyond these injection pathways, the next step for end-stage diffuse hip osteoarthritis is hip replacement. ChondroFiller injection sits at the point where cartilage repair surgery is no longer viable but where a patient has not yet reached — or chosen — the replacement threshold. That is the clinical position it is designed to fill.

What the clinical evidence shows

The largest published dataset for ChondroFiller comes from a knee cohort — worth naming upfront before the numbers land. The prospective Post-Market Clinical Follow-up (PMCF) study by Jerosch et al. recorded a mean IKDC (International Knee Documentation Committee) score improvement of 32.4 points at 36 months, comfortably exceeding the 16.7-point minimum clinically important difference for that scale. Alongside those functional gains, MRI assessment using the MOCART scoring system — a validated measure of repair tissue fill, integration, and surface congruity — showed progressive structural maturation: from 65.3 at four weeks to 81.6 at twelve months, and 84.3 at 36 months, indicating that more than 80% of the treated defect area was filled and well-integrated with surrounding tissue.

In hip-application data, improvements in the Modified Harris Hip Score of approximately 30 points have been reported, mirroring the knee findings and supporting the product's multi-joint CE indication, which covers use across the knee, hip, shoulder, ankle, and further joints. A dedicated hip-specific randomised controlled trial has not yet been published; hip application is supported by clinical experience and CE scope rather than an independent large-scale hip RCT, and that evidence base continues to mature.

What the broader intra-articular hip injection literature — including published randomised trials of hyaluronic acid and corticosteroid — establishes is that image-guided hip injection is a safe, well-tolerated delivery method. That is a statement about procedural safety specifically, not about ChondroFiller's efficacy in the hip joint; the two lines of evidence address different clinical questions.

Who is suitable for ChondroFiller injection

No upper age limit applies to ChondroFiller injection assessment at Lincolnshire Hip, and an X-ray showing advanced 'bone-on-bone' change does not automatically exclude a patient. Both points matter to people who have been told — sometimes incorrectly — that they are too worn for any intervention short of replacement.

The formal indication covers Kellgren-Lawrence Grade III/IV hip osteoarthritis: diffuse or advanced cartilage loss where focal surgical repair is no longer applicable. Within that group, suitability is evaluated through four clinical lenses:

• Physics — how load is distributed across the hip joint: alignment, gait pattern, and whether mechanical factors are concentrating stress on a damaged surface.
• Chemistry — the biological environment inside the joint: levels of active inflammation in the synovial fluid and the tissue state that a collagen scaffold would be placed into.
• Biology — capacity for tissue repair: remaining cartilage quality, bone stock, and systemic health factors that influence healing.
• Timing — where the patient sits in the degeneration timeline and whether enough structural substrate remains to support scaffold integration.

Contraindications include active joint or systemic infection, systemic inflammatory arthritis, immunosuppression, and poorly controlled diabetes.

Following assessment, the pathway is matched to the individual. Some patients proceed with ChondroFiller injection alone; others benefit from a keyhole procedure to address a contributing factor — femoroacetabular impingement or a loose body, for example — before or alongside the injection; and some are offered a combination plan. The assessment determines which fits.

Accessing ChondroFiller injection in Lincolnshire

ChondroFiller injection is available at Lincolnshire Hip's clinics in Grantham and Sleaford, meaning patients across Lincolnshire and the wider East Midlands can access this treatment without travelling to London. Professor Paul Lee, who introduced ChondroFiller as an outpatient injection in the UK, leads the service at both sites — a relevant point of confidence when considering a treatment still relatively new in its injectable form.

For patients who have reached the far end of the surgical preservation pathway — where cartilage loss is too diffuse for repair and hip replacement still feels premature — the injectable form of ChondroFiller represents something genuinely different: a regenerative scaffold placed during a clinic appointment rather than an operating theatre visit. That shift in access, for patients who have been told their options are exhausted, is part of the clinical case for it.

Assessment appointments are available without a GP referral. Initial consultation determines whether ChondroFiller injection, a combination approach, or an alternative pathway is most appropriate for that patient's hip.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.